Management ChangeJun 29, 2026, 08:01 AM
Rani Therapeutics Appoints Nicholas Maestas as New CFO
AI Summary
Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas Maestas as its new Chief Financial Officer, effective immediately. Maestas brings over a decade of financial leadership experience from clinical-stage biotechnology companies, including his previous role as CFO at Tempest Therapeutics. He succeeds Svai Sanford, who departed in May 2026 to pursue other opportunities. The company highlighted Maestas's expertise in biopharma capital markets and corporate strategy.
Key Highlights
- Nicholas Maestas appointed as Chief Financial Officer of Rani Therapeutics, effective immediately.
- Mr. Maestas succeeds Svai Sanford, who announced his departure in May 2026.
- Maestas brings over 10 years of financial leadership experience at clinical-stage biotechnology companies.
- He previously served as CFO and head of corporate strategy at Tempest Therapeutics.
- Maestas also held roles at Alector and Immune Design, contributing to a $300 million acquisition by Merck.
Price Impact
More from RANI